Q1 Earnings Forecast for BioNTech Issued By HC Wainwright

BioNTech SE (NASDAQ:BNTX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of BioNTech in a research report issued on Thursday, June 5th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($2.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $145.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2026 earnings at ($2.33) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at $0.90 EPS and FY2026 earnings at ($4.46) EPS.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.90 EPS.

Several other equities analysts have also recently issued reports on BNTX. JPMorgan Chase & Co. reduced their target price on BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Leerink Partners set a $112.00 target price on BioNTech in a research note on Monday, June 2nd. Canaccord Genuity Group reissued a “buy” rating and set a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. The Goldman Sachs Group assumed coverage on BioNTech in a research note on Thursday, May 29th. They set a “neutral” rating and a $110.00 target price on the stock. Finally, Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, BioNTech has an average rating of “Moderate Buy” and a consensus price target of $138.25.

BioNTech Price Performance

BNTX opened at $106.89 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The stock has a market capitalization of $25.70 billion, a PE ratio of -50.90 and a beta of 1.29. The stock’s 50 day moving average price is $99.87 and its 200-day moving average price is $108.36.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently made changes to their positions in the company. Banque Cantonale Vaudoise bought a new stake in BioNTech in the first quarter worth $36,000. Jones Financial Companies Lllp boosted its holdings in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after acquiring an additional 246 shares in the last quarter. Banque Transatlantique SA bought a new stake in BioNTech in the first quarter worth $80,000. Quintet Private Bank Europe S.A. boosted its holdings in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after acquiring an additional 700 shares in the last quarter. Finally, Allianz SE bought a new stake in BioNTech in the fourth quarter worth $90,000. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.